

### Amendments to the Claims

This listing of the claims as amended will replace all prior versions, and listings, of claims in the application.

1-55. **(Canceled)**

56. **(Previously Presented)** A method of treating a subject having a disorder or condition characterized by an unwanted immune response comprising administering an effective amount of a depleting anti-CD69 antibody molecule, wherein the anti-CD69 antibody specifically binds SEQ ID NO:2 to the subject.

57-58. **(Canceled)**

59. **(Currently Amended)** The method of claim 56, wherein said ~~depletor is a~~ depleting anti-CD69 antibody molecule is selected from the group consisting of: a humanized anti-CD69 antibody molecule, a human anti-CD69 antibody molecule, a chimeric anti-CD69 antibody molecule and a deimmunized anti-CD69 antibody molecule.

60. **(Original)** The method of claim 59, wherein said human anti-CD69 antibody molecule is a monoclonal antibody.

61-66. **(Canceled)**

67. **(Original)** The method of claim 56, wherein said disorder is an acute or chronic inflammatory disorder, or an immune disorder.

68. **(Original)** The method of claim 67, wherein said disorder is an autoimmune disorder.

69. **(Original)** The method of claim 56, wherein the disorder is selected from the group consisting of: rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjögren

syndrome, autoimmune diabetes, thyroiditis, and other organo-specific immune diseases, including psoriasis.

70. **(Withdrawn)** The method of claim 56, wherein the disorder is a neurological disorder, a gastrointestinal disorder, a cardiovascular disorder or a respiratory disorder.

71. **(Withdrawn)** The method of claim 70, wherein the disorder is a neurological disorder and the neurological disorder is selected from the group consisting of: multiple sclerosis, myasthenia gravis, and other neurological immune-mediated diseases.

72. **(Withdrawn)** The method of claim 70, wherein the disorder is a gastrointestinal disorder and the gastrointestinal disorder is selected from the group consisting of Crohn's disease, colitis, celiac disease, and hepatitis.

73. **(Withdrawn)** The method of claim 70, wherein the disorder is a respiratory disorder and the respiratory disorder is selected from the group consisting of: emphysema, and respiratory airways infections.

74. **(Withdrawn)** The method of claim 70, wherein the disorder is a cardiovascular disorder and the cardiovascular disorder is selected from the group consisting of: atherosclerosis, cardiomyopathy, rheumatic fever, endocarditis, vasculitis, and other immune-mediated diseases.

75. **(Withdrawn)** The method of claim 56, wherein the disorder is an allergic process or a hypersensitivity reaction (type I, II, III, and IV), including asthma, rhinitis, and other immune-mediated hypersensitivity reactions.

76. **(Withdrawn)** The method of claim 56, wherein the disorder is transplant or graft rejection.

77. **(Withdrawn)** The method of claim 56, wherein said disorder or condition is: acute lung injury, acute respiratory distress syndrome, asthma, bronchitis, cystic fibrosis,

reperfusion injury, nephritis, pancreatitis, artery occlusion, stroke, transplantation, ultraviolet light induced injury, vasculitis, and sarcoidosis.

78-104. **(Canceled)**

105. **(Previously Presented)** A method of treating a subject having a disorder or condition characterized by an unwanted immune response comprising administering an effective amount of a depleting anti-CD69 antibody molecule, wherein the anti-CD69 antibody specifically binds SEQ ID NO:2 to the subject, alone or conjugated to a second therapeutic agent.

106. **(Original)** The method of claim 105, wherein said second therapeutic agent is selected from the group consisting of: chemotherapeutic agents; radioisotopes; and cytotoxins.

107. **(Original)** The method of claim 105, wherein the antibody is a monoclonal antibody.

108. **(Original)** The method of claim 107, wherein the monoclonal antibody is a human antibody.